Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases

被引：0
|
作者：
Costa, Luis
Fizazi, Karim
Saad, Fred
Brown, Janet Elizabeth
Von Moos, Roger
Oudard, Stephane
Sternberg, Cora N.
Ganju, Vinod
Miller, Kurt
Wang, Huei
Maniar, Tapan
Braun, Ada
机构：
[1] Hosp Santa Maria, Lisbon, Portugal
[2] Inst Med Mol, Lisbon, Portugal
[3] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[4] Univ Montreal Hosp Ctr, CRCHUM, Montreal, PQ, Canada
[5] Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[6] Kantonsspital Graubunden, Chur, Switzerland
[7] Georges Pompidou European Hosp, Paris, France
[8] San Camillo Forlanini Hosp, Rome, Italy
[9] Peninsula Oncol Ctr, Frankston, Australia
[10] Charite, D-13353 Berlin, Germany
[11] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5079
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Use of zoledronic acid and a RANK ligand inhibitor in the palliative treatment of cancers of the prostate with bone metastases
    Mushigin, S. V.
    Sokov, D. G.
    Rusakov, I. G.
    ONKOUROLOGIYA, 2013, 9 (04): : 52 - 54
  • [22] Denosumab: a new option in the treatment of bone metastases from urological cancers
    Yuasa, Takeshi
    Yamamoto, Shinya
    Urakami, Shinji
    Fukui, Iwao
    Yonese, Junji
    ONCOTARGETS AND THERAPY, 2012, 5 : 221 - 229
  • [23] COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR TREATMENT OF BONE METASTASES IN ADVANCED CANCER PATIENTS: AN INTEGRATED ANALYSIS OF 3 PIVOTAL TRIALS
    Lipton, A.
    Siena, S.
    Rader, M.
    Bilynskyy, B.
    Viniegra, M.
    Richardson, G.
    Beuzeboc, P.
    Clemens, M.
    Ke, C.
    Jun, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 380 - 380
  • [24] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Xie, Jipan
    Namjoshi, Madhav
    Wu, Eric Q.
    Parikh, Kejal
    Diener, Melissa
    Yu, Andrew P.
    Guo, Amy
    Culver, Kenneth W.
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (08): : 621 - 634
  • [25] Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases
    Wu, E. Q.
    Xie, J.
    Signorovitch, J.
    Diener, M.
    Sorg, R.
    Namjoshi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [26] Cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases from solid tumours in Spain
    Duran, I.
    Segui, M. A.
    Isla, D.
    Oyagueez, I.
    Roldan, C.
    Casado, M. A.
    Lothgren, M.
    Hechmati, G.
    Gutierrez, L.
    Gasquet, J. A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S334 - S334
  • [27] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Rader, Michael
    Goessl, Carsten
    Cong, Ze
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (01): : 74 - 75
  • [28] Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials
    Chen, Fengxia
    Pu, Feifei
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (7-8) : 453 - 459
  • [29] Efficacy and Safety of Denosumab Versus Zoledronic Acid in Patients With Bone Metastases A Systematic Review and Meta-analysis
    Sun, Lei
    Yu, Shiying
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (04): : 399 - 403
  • [30] Treatment with zoledronic acid subsequent to treatment with denosumab
    Solling, Anne Sophie
    Harslof, Torben
    Langdahl, Bente Lomholt
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 60 - 60
12345